Engineering the perfect (bacterial) cancer therapy
Open accessThe DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Abstract
Bacterial therapies possess many unique mechanisms for treating cancer that are unachievable with standard methods. Bacteria can specifically target tumours, actively penetrate tissue, are easily detected and can controllably induce cytotoxicity. Over the past decade, Salmonella, Clostridium and other genera have been shown to control tumour growth and promote survival in animal models. In this Innovation article I propose that synthetic biology techniques can be used to solve many of the key challenges that are associated with bacterial therapies, such as toxicity, stability and efficiency, and can be used to tune their beneficial features, allowing the engineering of 'perfect' cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in certain cases, injection of intratumoral bacteria or their antigens may conversely provide immunostimulatory effects, as demonstrated by Coley’s toxins and recent developments in bacterial cancer therapy (5, 105, 106).”
From The microbiome and human cancer (2021) · cites this paper as [105]
In the citing paper
“BCT is re-gaining attention through synthetic biology techniques that programmatically limit systemic toxicities while enhancing regional antitumor immunity (105, 106).”
From The microbiome and human cancer (2021) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guzman, L. M., Belin, D., Carson, M. J., & Beckwith, J. (1995) · Journal of Bacteriology · doi:10.1128/jb.177.14.4121-4130.1995 · Cited by 4,935
(1989) · PubMed · Cited by 3,343
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805 · cited 1×
“Many treatments, including chemotherapy and radiation, are toxic to normal tissue and cannot completely destroy all cancer cell”
BackgroundTumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Automated design of synthetic ribosome binding sites to control protein expression
Salis, H. M., Mirsky, E. A., & Voigt, C. A. (2009) · Nature Biotechnology · doi:10.1038/nbt.1568 · Cited by 1,844
CONTRIBUTION TO THE KNOWLEDGE OF SARCOMA
COLEY, W. B. (1891) · Annals of Surgery · doi:10.1097/00000658-189112000-00015 · Cited by 715
Toso, J. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.142 · Cited by 614 · cited 1×
“This containment is one possible reason that attenuated Salmonella had limited success in reducing tumour growth in human trial”
BackgroundCombination bacteriolytic therapy for the treatment of experimental tumors
Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W., & Vogelstein, B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251543698 · Cited by 563 · cited 1×
“For propulsion and sensing, bacteria have flagella that enable tissue penetratio”
BackgroundCombinatorial engineering of intergenic regions in operons tunes expression of multiple genes
Pfleger, B. F., Pitera, D. J., Smolke, C. D., & Keasling, J. D. (2006) · Nature Biotechnology · doi:10.1038/nbt1226 · Cited by 536 · cited 1×
“, including gene copy number, promoter strength, optimized codons, bacterial metabolism, mRNA secondary structur”
Background
Cited by
Items 301–400 of 905
Optically activatable photosynthetic bacteria-based highly tumor specific immunotheranostics
Yang, X., Komatsu, S., Reghu, S., & Miyako, E. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101100 · Cited by 39
Avengers against cancer: A new era of nano-biomaterial-based therapeutics
Kumar, N., Fazal, S., Miyako, E., Matsumura, K., & Rajan, R. (2021) · Materials Today · doi:10.1016/j.mattod.2021.09.020 · Cited by 41
Surface programmed bacteria as photo-controlled NO generator for tumor immunological and gas therapy
Chen, B., Zhang, X., Cheng, L., Chen, X., Tang, J., Zhang, P., Wang, C., & Liu, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.030 · Cited by 38
Challenges for the European governance of synthetic biology for human health
Douglas, C. M. W., & Stemerding, D. (2014) · Life Sciences Society and Policy · doi:10.1186/s40504-014-0006-7 · Cited by 38
Engineered bacteria for augmented in situ tumor vaccination
Shen, X., Zhu, C., Liu, X., Zheng, H., Wu, Q., Xie, J., Huang, H., Liao, Z., Shi, J., Nan, K., et al. (2023) · Biomaterials Science · doi:10.1039/d2bm01593e · Cited by 38
Raman, V., Deshpande, C. P., Khanduja, S., Howell, L. M., Dessel, N. V., & Forbes, N. S. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.09.006 · Cited by 38
Self-citationGupta, A., Nishchaya, K., Saha, M., Naik, G. A. R. R., Yadav, S., Srivastava, S., Roy, A. A., Moorkoth, S., Mutalik, S., & Dhas, N. L. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105401 · Cited by 46
The emerging landscape of engineered bacteria cancer therapies
Ballister, E. R., Michels, A., Vincent, R. L., Kreindler, L., Chowdhury, S., Upadhaya, S., Saez-Ibañez, A. R., Tu, T., Gottweis, J., & Danino, T. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02623-x · Cited by 35
Zhou, S., Zhao, Z., Lin, Y., Gong, S., Li, F., Pan, J., Li, X., Gao, Z., & Zhao, A. Z. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1177683 · Cited by 36
“Many bacterial genera, such as different variants of Salmonella,(4) Clostridium 5 and Streptococcus pyogenes,(6) have been shown to have successful suppressive effects on multiple animal tumor models, the most notable of which is pancreatic cancer.(7)”
BackgroundKocijancic, D., Felgner, S., Schauer, T., Frahm, M., Heise, U., Zimmermann, K., Erhardt, M., & Weiß, S. (2017) · Oncotarget · doi:10.18632/oncotarget.18392 · Cited by 37
“Furthermore, strategies of combination therapy [18] or changes in dosing regimens as well as alternate routes of inoculation could aid the optimization process.”
The motility regulator flhDC drives intracellular accumulation and tumor colonization of Salmonella
Raman, V., Dessel, N. V., O’Connor, O. M., & Forbes, N. S. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0490-z · Cited by 35
Self-citationJiang, Y., Sigmund, F., Reber, J., Deán‐Ben, X. L., Glasl, S., Kneipp, M., Estrada, H., Razansky, D., Ntziachristos, V., & Westmeyer, G. G. (2015) · Scientific Reports · doi:10.1038/srep11048 · Cited by 35
The inhibition of indoleamine 2, 3-dioxygenase 1 by connexin 43
Lin, H.-C., Yang, C., Kuan, Y.-D., Wang, W.-K., Chang, W., & Lee, C. (2017) · International Journal of Medical Sciences · doi:10.7150/ijms.20661 · Cited by 36
“As a facultative anaerobe with motility, Salmonella is more preferentially reaching, accumulating and proliferating in the tumor region than other strains or drugs [22-23].”
BackgroundStreptococcal bacterial components in cancer therapy
Marzhoseyni, Z., Shojaie, L., Tabatabaei, S. A., Movahedpour, A., Safari, M., Esmaeili, D., Mahjoubin‐Tehran, M., Jalili, A., Morshedi, K., Khan, H. Z., et al. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00308-6 · Cited by 36
Integration of Salmonella into Combination Cancer Therapy
Al-Saafeen, B. H., Fernández-Cabezudo, M. J., & al-Ramadi, B. K. (2021) · Cancers · doi:10.3390/cancers13133228 · Cited by 40
“It was suggested that nutrient deprivation and release of bacterial toxins could underlie apoptosis promotion [51,52].”
BackgroundInactive Trojan Bacteria as Safe Drug Delivery Vehicles Crossing the Blood–Brain Barrier
Lu, J., Ding, J., Chu, B., Ji, C., Zhang, Q., Xu, Y., Song, B., Wang, H., & He, Y. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c00563 · Cited by 36
Revolutionizing cancer treatment: The power of cell-based drug delivery systems
Qi, L., Liu, T., Han, Z., Zhao, J., Fan, X., Wang, H., Song, J., Ye, H., & Sun, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.023 · Cited by 33
Wang, L., Ji, P., Yu, J., Qiu, S., An, B., Huo, M., & Shi, J. (2024) · Science Advances · doi:10.1126/sciadv.adp7540 · Cited by 40
“…microbes could selectively colonize and proliferate inside the tumor region, presenting pronounced organ selectivity with a tumor/liver accumulation ratio of higher than 1000:1, conferring the tumor-targeting performance of the living microbes with obligate or facultative anaerobes ( 8 , 9 ).”
Wang, H., Zhan, H., Pan, B., Zeng, L., Chen, Z., Liu, S., Zhang, Q., Hong, X., Lu, J., Lin, X., et al. (2025) · Advanced Materials · doi:10.1002/adma.202501565 · Cited by 52
Advances in Anticancer Protein Delivery using Micro‐/Nanoparticles
Sun, W., Lü, Y., & Gu, Z. (2014) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.201400140 · Cited by 35
Dynamic and tunable metabolite control for robust minimal-equipment assessment of serum zinc
McNerney, M. P., Michel, C. L., Kishore, K., Standeven, J., & Styczynski, M. P. (2019) · Nature Communications · doi:10.1038/s41467-019-13454-1 · Cited by 34
Bioengineered smart bacterial carriers for combinational targeted therapy of solid tumours
Alizadeh, S., Esmaeili, A., Barzegari, A., Rafi, M. A., & Omidi, Y. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1737087 · Cited by 34
Therapeutic potential of microbial modulation in pancreatic cancer
Chandra, V., & McAllister, F. M. (2021) · Gut · doi:10.1136/gutjnl-2019-319807 · Cited by 37
Dai, Y., Toley, B. J., Swofford, C. A., & Forbes, N. S. (2013) · Biotechnology and Bioengineering · doi:10.1002/bit.24816 · Cited by 36
Self-citationBioinspired Engineering of a Bacterium‐Like Metal–Organic Framework for Cancer Immunotherapy
Chen, P., Pan, W., Miao, Y., Liu, Y.-Y., Luo, P.-K., Phung, H. N., Wu, W., Ting, Y.-H., Yeh, C.-Y., Chiang, M., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003764 · Cited by 33
Engineering versatile nano-bacteria hybrids for efficient tumor therapy
Wang, W., Yu, W., Li, G., Huang, H., Song, X., Yu, L., & Chen, Y. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215178 · Cited by 35
Harnessing Bacterial Agents to Modulate the Tumor Microenvironment and Enhance Cancer Immunotherapy
Thomas, C. J., Delgado, K., Sawant, K., Roy, J., Gupta, U., Song, C. S., Poojary, R., de Figueiredo, P., & Song, J. J. (2024) · Cancers · doi:10.3390/cancers16223810 · Cited by 35
Traoré, M. A., Damico, C. M., & Behkam, B. (2014) · Applied Physics Letters · doi:10.1063/1.4900641 · Cited by 32
Considerations for setting occupational exposure limits for novel pharmaceutical modalities
Graham, J. C., Hillegass, J., & Schulze, G. E. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104813 · Cited by 34
“GM bacteria can bypass problems associated with conventional cancer chemotherapies, such as poor selectivity and limited tumor penetrability, and can be finely engineered to sense and respond to the tumor microenvironment (Forbes, 2010).”
Gao, Z., Zhang, E., Zhao, H., Xia, S., Bai, H., Huang, Y., Lv, F., Liu, L., & Wang, S. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c01493 · Cited by 32
Development of a TNF-α-mediated Trojan Horse for bacteria-based cancer therapy
Hu, C.-W., Chang, Y.-C., Liu, C.-H., Yu, Y., & Mou, Y. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.04.008 · Cited by 36
Designer bacteria as intratumoural enzyme biofactories
Lehouritis, P., Hogan, G. E., & Tangney, M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.012 · Cited by 33
“Thirdly, the genomic capacity of bacteria is far greater than that of viruses, making them more amenable to genetic engineering [20].”
BackgroundSynthetic biology expands chemical control of microorganisms
Ford, T. J., & Silver, P. A. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.05.012 · Cited by 32
“There has also been extensive work using attenuated and engineered strains of bacteria to combat cancer (Reviewed in [55]).”
BackgroundAdvances in bacteria‐based drug delivery systems for anti‐tumor therapy
Han, S., Yifei, S., Wu, X., Zhanbo, Q., Xiang, Y., & Yang, X. (2024) · Clinical & Translational Immunology · doi:10.1002/cti2.1518 · Cited by 39
“24 Bacteria exhibit potential for delivering anti-tumor drugs, aiding drug accumulation at the tumor site, preventing drug leakage, and ultimately enhancing therapeutic efficacy against tumors.”
BackgroundDai, X., Liu, Z., Zhao, X., Guo, K., Ding, X., Xu, F., & Zhao, N. (2024) · Advanced Materials · doi:10.1002/adma.202407927 · Cited by 32
Engineering bacteria for cancer therapy
Harimoto, T., & Danino, T. (2019) · Emerging Topics in Life Sciences · doi:10.1042/etls20190096 · Cited by 35
Engineered Bacteriophage T7 as a Potent Anticancer Agent in vivo
Hwang, Y. J., & Myung, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.491001 · Cited by 31
“Bacteria are better at infiltrating inside tumors thanks to their motility, which phages do not have (Forbes, 2010).”
BackgroundTLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy
González, C., Williamson, S. L., Gammon, S. T., Glazer, S. E., Rhee, J. H., & Piwnica-Worms, D. R. (2023) · Communications Biology · doi:10.1038/s42003-022-04403-8 · Cited by 34
Broadway, K. M., Suh, S., Behkam, B., & Scharf, B. E. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.006 · Cited by 31
Saltzman, D. A., Augustin, L. B., Leonard, A. S., Mertensotto, M. J., & Schottel, J. L. (2017) · Surgery · doi:10.1016/j.surg.2017.09.036 · Cited by 31
Sialidase-Chimeric Bioengineered Bacteria for Tumor-Sialoglycan-Triggered Solid Tumor Therapy
Chen, Q., Zhang, Y., Bao, P., & Zhang, X. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c03049 · Cited by 32
Engineered bacteria: Strategies and applications in cancer immunotherapy
Zhang, S., Li, R., Xu, Y., Liu, R., Sun, D., & Dai, Z. (2024) · Fundamental Research · doi:10.1016/j.fmre.2024.11.001 · Cited by 35
“As living organisms, unlike other non-living carriers or drugs, bacteria can overcome entropy increase and thus generate activities to cope with the complex environment and actively seek out tumors in vivo [ 12 ].”
InfluentialParker, M. T., & Kunjapur, A. M. (2020) · Health Security · doi:10.1089/hs.2020.0010 · Cited by 30
“108 Engineered microbes provide an opportunity to selectively deploy targeted cleanup agents that can detect and destroy environmental toxins, 109,110 such as those for aromatic or chlorinated pollutants, as first re-ported in the 1980s.”
Engineering Living Bacteria for Cancer Therapy
Rong, L., Lei, Q., & Zhang, X. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01286 · Cited by 32
Chen, X. J., Wang, B., Thompson, I. P., & Huang, W. E. (2021) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00223 · Cited by 34
Drug-loaded nanoparticles conjugated with genetically engineered bacteria for cancer therapy
Du, Y., Li, L., Zhang, Z., Tang, Y., Ou, X., Wang, Y., & Zou, J. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.03.049 · Cited by 32
Chen, C., Wang, P., Chen, H., Wang, X., Halgamuge, M. N., Chen, C., & Song, T. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c24154 · Cited by 30
Engineering Cyborg Bacteria Through Intracellular Hydrogelation
Contreras-Llano, L. E., Liu, Y., Henson, T., Meyer, C. C., Baghdasaryan, O., Khan, S. A., Lin, C., Wang, A., Hu, C. J., & Tan, C. (2023) · Advanced Science · doi:10.1002/advs.202204175 · Cited by 34
Hong, H. H., Lim, D., Kim, G., Park, S., Kim, H. S., Hong, Y., Choy, H. E., & Min, J. (2014) · Cell Cycle · doi:10.4161/15384101.2014.949527 · Cited by 30
“typhimurium has several advantages over other strains: (1) it can grow in aerobic or anaerobic conditions, both of which are found in solid tumors; (2) it has specialized systems that mediate the invasion of epithelial cells and macrophages; and (3) there is a vast body of information on its genetics, which facilitate…”
BackgroundPotentiating bacterial cancer therapy using hydroxychloroquine liposomes
Wang, Y., Zhou, Z., Chen, W., Qin, M., Zhang, Z., Gong, T., & Sun, X. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.046 · Cited by 31
Murakami, T., Hiroshima, Y., Miyake, K., Kiyuna, T., Endo, I., Zhao, M. D., & Hoffman, R. M. (2019) · Cells · doi:10.3390/cells8060599 · Cited by 30
“Live bacteria can actively penetrate tumors to reach lesions distant from blood vessels, where chemotherapeutic drugs cannot be delivered, and damage malignant cells by several cytotoxic mechanisms [2].”
BackgroundXiang, S., Yao, Q., Khan, A., & Wang, D. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101049 · Cited by 36
Development of Aspirin-Inducible Biosensors in Escherichia coli and SimCells
Chen, J. X., Steel, H., Wu, Y.-H., Wang, Y., Xu, J., Rampley, C. P. N., Thompson, I. P., Papachristodoulou, A., & Huang, W. E. (2019) · Applied and Environmental Microbiology · doi:10.1128/aem.02959-18 · Cited by 32
“Synthetic biology has the potential to engineer bacteria for disease diagnosis (1) and cancer therapy (2).”
Novel Delivery Systems for Checkpoint Inhibitors
Lamichhane, P., Deshmukh, R. R., Brown, J. K., Jakubski, S., Parajuli, P., Nolan, T. A., Raja, D. S., Badawy, M., Yoon, T., Zmiyiwsky, M., et al. (2019) · Medicines · doi:10.3390/medicines6030074 · Cited by 32
“Since this method is not always feasible in patients and given that bacteria have been found to be present and preferentially grow in tumors [128], it will be important to determine if oral administration of bacteria could result in similar anti-tumor effects compared to intratumoral injections.”
MethodPerspectives on Oncolytic Salmonella in Cancer Immunotherapy—A Promising Strategy
Wang, D., Wei, X., Kalvakolanu, D. V., Guo, B., & Zhang, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.615930 · Cited by 32
“, host immune response against tumors (14).”
Mehta, T. R., Vercruysse, K. P., Johnson, T. L., Ejiofor, A. O., Myles, E. L., & Quick, Q. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3525 · Cited by 31
“The utility of bacteria as agents for the treatment of cancer was described over a century ago and continues to be investigated for their therapeutic value as delivery agents for anti-cancer drugs and vectors for gene therapy (1-3).”
BackgroundInfluentialSun, D., Li, Y., Yin, X., Fan, Y., Liu, J., Wang, Y., Liu, X., Bai, G., Li, K., Shi, Y., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c11412 · Cited by 33
Pierce, K. M., Miklavcic, W. R., Cook, K. P., Hennen, M. S., Bayles, K. W., Hollingsworth, M. A., Brooks, A. E., Pullan, J. E., & Dailey, K. M. (2021) · Nanomaterials · doi:10.3390/nano11113018 · Cited by 31
Oncolytic bacteria: past, present and future
Rius‐Rocabert, S., Llinares, F., Pozuelo, M. J., García, A., & Nistal‐Villán, E. (2019) · FEMS Microbiology Letters · doi:10.1093/femsle/fnz136 · Cited by 30
Advancement of Engineered Bacteria for Orally Delivered Therapeutics
Guo, P., Wang, S., Yue, H., Zhang, X., Ma, G., Li, X., & Wei, W. (2023) · Small · doi:10.1002/smll.202302702 · Cited by 30
Understanding and harnessing triple-negative breast cancer-related microbiota in oncology
Devoy, C., Bueso, Y. F., & Tangney, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1020121 · Cited by 33
Awareness of intratumoral bacteria and their potential application in cancer treatment
Liang, Y., Li, Q., Liu, Y., Guo, Y., & Li, Q. (2023) · Discover Oncology · doi:10.1007/s12672-023-00670-x · Cited by 33
“The ideal cancer treatment should preferably be able to target any specific tumor tissue, respond appropriately to external stimuli, and adjust properly to the body’s environment or even become self-sufficient within the body [77].”
BackgroundTao, C., Miao, X., Yan, J., Xiao, X., Wu, R., Cao, Q., Wang, Z., Lv, R., Ge, T., & Liu, J. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.08.044 · Cited by 29
Precise control of lycopene production to enable a fast-responding, minimal-equipment biosensor
McNerney, M. P., & Styczynski, M. P. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.07.004 · Cited by 28
“Cells are already being engineered to specifically deliver drugs to tumors (Forbes 2010, Din et al. 2016, Hosseinidoust et al. 2016) and to produce different drugs based on what is needed in low-resource settings (Choi et al. 2014, Perez-Pinera et al. 2016).”
BackgroundNucleoside Diphosphate Kinase-3 ( NME3 ) Enhances TLR5-Induced NF κ B Activation
Flentie, K., González, C., Kocher, B. A., Wang, Y., Zhu, H., Marasa, J. C., & Piwnica-Worms, D. R. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0603 · Cited by 28
Li, L., Zhang, R., Chen, L., Tian, X., Li, T., Pu, B., Ma, C., Ji, X., Ba, F., Xiong, C., et al. (2022) · Advanced Science · doi:10.1002/advs.202203652 · Cited by 29
Murine solid tumours as a novel model to study bacterial biofilm formation in vivo
Pawar, V., Crull, K., Komor, U., Kasnitz, N., Frahm, M., Kocijancic, D., Westphal, K., Leschner, S., Wolf, K., Loessner, H., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12258 · Cited by 28
Targeted Drug Delivery in Lipid-like Nanocages and Extracellular Vesicles
Av, S., Kostin, N. N., Ovchinnikova, L. A., Lomakin, Y. A., & Kudriaeva, A. A. (2019) · Acta Naturae · doi:10.32607/20758251-2019-11-2-28-41 · Cited by 26
Development of 3D‐Printed Magnetic Micro‐Nanorobots for Targeted Therapeutics: the State of Art
Hu, N., Ding, L., Liu, Y., Wang, K., Zhang, B., Yin, R., Zhou, W., Bi, Z., & Zhang, W. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300018 · Cited by 29
A Safe Bacterial Microsyringe for In Vivo Antigen Delivery and Immunotherapy
Gouëllec, A. L., Chauchet, X., Laurin, D., Aspord, C., Verove, J., Wang, Y., Genestet, C., Trocmé, C., Ahmadi, M., Martin, S., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.41 · Cited by 25
Measuring Growth and Gene Expression Dynamics of Tumor-Targeted S. Typhimurium Bacteria
Danino, T., Prindle, A. B., Hasty, J., & Bhatia, S. N. (2013) · Journal of Visualized Experiments · doi:10.3791/50540 · Cited by 25
Small molecule signaling, regulation, and potential applications in cellular therapeutics
McNerney, M. P., & Styczynski, M. P. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1405 · Cited by 28
“For example, Salmonella strains that are auxotrophic for leucine and arginine, which are produced by dying tumor tissue, show increased tumor specificity regardless of any payload.(22,27,28) Strains that were auxotrophic for purines (also produced by necrotic tumor tissue) have been used to transform prodrugs into the…”
BackgroundTargeted drug delivery therapies inspired by natural taxes
Nguyen, H. V., & Faivre, V. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.005 · Cited by 27
Inhibition of acute leukemia with attenuated Salmonella typhimurium strain VNP20009
Li, M., Lü, M., Lai, Y., Zhang, X., Li, Y., Mao, P., Liang, Z., Mu, Y., Lin, Y. C., Zhao, A. Z., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110425 · Cited by 27
Anaerobe‐Inspired Anticancer Nanovesicles
Qian, C., Feng, P., Yu, J., Chen, Y., Hu, Q., Sun, W., Xiao, X., Hu, X., Bellotti, A., Shen, Q., et al. (2017) · Angewandte Chemie · doi:10.1002/ange.201611783 · Cited by 26
Lin, H., Liu, H.-H., Lin, C., Kao, M.-C., Chen, Y., Chiang-Ni, C., Jiang, Z.-P., Huang, M.-Z., Lin, C., Lo, U., et al. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00223 · Cited by 26
“Bacterial toxins can be developed as treatment modalities for tumors (Forbes, 2010).”
BackgroundMultifaceted Engineered Biomimetic Nanorobots Toward Cancer Management
Nehru, S., Misra, R., & Bhaswant, M. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c01352 · Cited by 30
Vasculature Disruption Enhances Bacterial Targeting of Autochthonous Tumors
Drees, J. J., Mertensotto, M. J., Augustin, L. B., Schottel, J. L., & Saltzman, D. A. (2015) · Journal of Cancer · doi:10.7150/jca.12491 · Cited by 24
“This characteristic is highly reproducible in murine tumors developed from transplanted cells or tissues [5].”
BackgroundInfluentialA Novel Balanced-Lethal Host-Vector System Based on glmS
Kim, K., Jeong, J., Lim, D., Hong, Y., Yun, M., Min, J., Kwak, S., & Choy, H. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060511 · Cited by 24
“Cancer therapy using bacteria takes advantage of multiple types of bacteria, including Salmonella, Escherichia, Clostridium, Proteus and Streptococcus, due to their tendency to accumulate preferentially in tumor tissue, although the mechanism that mediates this remains unknown [1].”
BackgroundOßwald, A., Sun, Z., Grimm, V., Ampem, G., Riegel, K., Westendorf, A. M., Sommergruber, W., Otte, K., Dürre, P., & Riedel, C. U. (2015) · Microbial Cell Factories · doi:10.1186/s12934-015-0383-5 · Cited by 29
“The most frequently investigated bacterial gene delivery systems to target solid tumors are, however, facultative or obligate anaerobes of the genera Salmonella, Clostridium, and Bifidobacterium (reviewed in [12–15]).”
BackgroundQuintero, D. A., Carrafa, J., Vincent, L., & Bermudes, D. G. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.26026 · Cited by 24
“Among the live bacteria now implicated with potentially positive therapeutic effects against cancer is Salmonella, which is currently being studied by a number of investigators for its tumor-targeted properties (see Forbes, 2010 and Hoffman, 2015 for reviews).”
TumbleScore: Run and Tumble Analysis for Low Frame-Rate Motility Videos
Pottash, A. E., McKay, R., Virgile, C., Ueda, H., & Bentley, W. E. (2017) · BioTechniques · doi:10.2144/000114493 · Cited by 24
Engineering Escherichia coli for Light-Activated Cytolysis of Mammalian Cells
Magaraci, M. S., Veerakumar, A., Qiao, P. L., Amurthur, A., Lee, J. Y., Miller, J. S., Goulian, M., & Sarkar, C. A. (2014) · ACS Synthetic Biology · doi:10.1021/sb400174s · Cited by 26
Advances in Nanomaterials for Immunotherapeutic Improvement of Cancer Chemotherapy
Liu, J., Li, B., Li, L., Ming, X., & Xu, Z. P. (2024) · Small · doi:10.1002/smll.202403024 · Cited by 24
Wang, J., Wang, J., Yu, Z., Wen, H., Zhao, C.-S., Zhong, J., Xiao, C., Li, Y., Xu, J., Wang, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202411813 · Cited by 36
Ashu, E. E., Xu, J., & Yuan, Z. (2019) · Journal of Cancer · doi:10.7150/jca.31699 · Cited by 26
“Engineering a bacterium that targets tumors or cancerous cells, produces cytotoxic or immunogenic proteins, self-propels and responds to triggering signals, senses the local environment and produces externally detectable signals is not so far-fetched anymore.(196) However, despite the overall enthusiasm about the futu…”
BackgroundSynthetic immunity by remote control
Gamboa, L., Zamat, A. H., & Kwong, G. A. (2020) · Theranostics · doi:10.7150/thno.41305 · Cited by 22
“Remarkably, recent studies have shown that certain strains of bacteria preferentially colonize and grow in tumors, thriving on the nutrients of the necrotic core while masked from immune surveillance by tumor-induced suppression [167-169].”
BackgroundNguyen, D.-H., You, S.-H., Vo, A.-T. N., Ngo, H. T.-T., Nguyen, K. V., Duong, M. T.-Q., Choy, H. E., Song, M., Hong, Y., & Min, J. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01624-x · Cited by 22
Genome Engineering of the Fast-Growing Mycoplasma feriruminatoris toward a Live Vaccine Chassis
Talenton, V., Baby, V., Gourgues, G., Mouden, C., Claverol, S., Vashee, S., Blanchard, A., Labroussaa, F., Jores, J., Arfi, Y., et al. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00062 · Cited by 23
Peptides as Diagnostic, Therapeutic, and Theranostic Tools: Progress and Future Challenges
Thakur, R., Suri, C. R., Kaur, I. P., & Rishi, P. (2022) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2022040322 · Cited by 24
Wang, W., Fan, J., Zhang, C., Huang, Y., Chen, Y., Fu, S., & Wu, J. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127668 · Cited by 25
Hoffman, R. M. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.644534 · Cited by 23
“Fehleisen and Coley in the late 19th and early 20th centuries treated patients with Streptococcus pyrogenes [1-4].”
BackgroundLearning from Clostridium novyi-NT: How to defeat cancer
Wang, L., Wang, Q., Tian, X., & Shi, X. (2017) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.204841 · Cited by 23
Living, Self‐Replicating Ferrofluids for Fluidic Transport
Mirkhani, N., Christiansen, M. G., & Schuerle, S. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003912 · Cited by 23
A Phytase-Based Reporter System for Identification of Functional Secretion Signals in Bifidobacteria
Oßwald, A., Westermann, C., Sun, Z., & Riedel, C. U. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128802 · Cited by 24
“In addition to their reported health-promoting effects, some strains of bifidobacteria were shown colonise solid tumours in various mouse models [17–20] and thus have gained increasing interest as vectors for delivery of therapeutic genes in cancer therapy [21–23].”
BackgroundBacterial carrier-mediated drug delivery systems: a promising strategy in cancer therapy
Yan, S., Gan, Y., Xu, H., & Piao, H. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1526612 · Cited by 24
“In contrast to inactivated bacteria, live bacteria can actively target most tumors, including metastases (Forbes, 2010), and most live bacteria can better penetrate and colonize intratumoral tissues depending on the fl agellum (Felgner et al., 2018).”
Chen, M., & Liu, J. (2025) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5c00271 · Cited by 24
Bringing next-generation therapeutics to the clinic through synthetic biology
Bugaj, L. J., & Schaffer, D. V. (2012) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.04.009 · Cited by 22
Darvishi, B., Samadi, M., Majidzadeh‐A, K., Salehi, M., Jalili, N., Noorinejad, Z., Mosayebzadeh, M., Mohammadnejad, A., Sharifkhatibi, A., Moradi‐Kalbolandi, S., et al. (2021) · Journal of Biological Engineering · doi:10.1186/s13036-021-00269-2 · Cited by 23
Kung, Y.-J., Lam, B. K., Tseng, S.-H., MacDonald, A., Tu, H.-F., Wang, S., Lin, J. W., Tsai, Y. C., Wu, T. ‐., & Hung, C. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00841-y · Cited by 23
“Strategies range from systemic infection with a plethora of microbial species to engineered organisms programmed to deliver chemoattractants, chemotherapeutics, or other cytotoxic agents to specific tissues [3].”
Background
Metadata
- Authors
- Forbes, N. S.
- Affiliations
- University of Massachusetts Amherst (US)
- Corresponding author
- Forbes, Neil S.
- ORCID
- Forbes, Neil S.
- Venue
- Nature Reviews Cancer
- Published
- 2010-10-14
- Volume
- 10
- Issue
- 11
- Pages
- 785-794
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3756932
- OpenAlex
- W1979507175
- Cited by
- 905
- References
- 141
- Citations by year
- 2026: 76 · 2025: 89 · 2024: 95 · 2023: 76 · 2022: 81 · 2021: 81 · 2020: 69 · 2019: 47 · 2018: 47 · 2017: 46 · 2016: 42 · 2015: 40 · 2014: 45 · 2013: 37 · 2012: 20
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA120825, CA120825)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- bacterial cancer therapy, synthetic biology, Salmonella, Clostridium, tumor targeting, bacterial cytotoxicity, bacterial stability, bacterial toxicity, tumor growth control, cancer immunotherapy
- MeSH terms
- Animals, Antineoplastic Agents, Clostridium, Genetic Engineering, Humans, Neoplasms, Salmonella
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.